Applied Genetic Technologies (AGTC) Reports Q2 EPS of 17c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/26/2026

1. ORCL
2. SPY
3. ANT
4. META
5. FICO
6. LLY
7. TSLA
8. GMAB
9. ACCV
10. CART

Go back to Applied Genetic Technologies (AGTC) Reports Q2 EPS of 17c

AGTC Announces Financial Results for the Quarter Ended December 31, 2015

February 8, 2016 4:01 PM EST

GAINESVILLE, Fla., and CAMBRIDGE, Mass., Feb. 08, 2016 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (NASDAQ: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, with a primary focus on ophthalmology, today announced financial results for the quarter ended December 31, 2015. The company also announced that Biogen (NASDAQ: BIIB) has selected adrenoleukodystrophy (ALD) as the first publicly announced of the three discovery programs under its collaboration with AGTC.

Over the past several months, AGTC has met several... More